Kammula, Ashwin V. http://orcid.org/0000-0001-5284-721X
Schäffer, Alejandro A. http://orcid.org/0000-0002-2147-8033
Rajagopal, Padma Sheila
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Ruppin, Eytan http://orcid.org/0000-0002-7862-3940
Funding for this research was provided by:
Natioinal Institutes of Health Intramural Research Program, NCI
National Institutes of Health Intramural Research Program, NCI
Article History
Received: 16 May 2023
Accepted: 15 March 2024
First Online: 23 March 2024
Competing interests
: R.K. has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance and from the NCI; as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc. and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. E.R. is a co-founder of Medaware Ltd, Metabomed Ltd and of Pangea Biomed, Ltd (divested from the latter). E.R. serves as a non-paid scientific consultant to Pangea Biomed, Ltd. The other authors declare that they have no potential competing interests.